UY30253A1 - Benzoimidazol -2-il pirimidinas y pirazinas como moduladores del receptor h4 de histamina - Google Patents

Benzoimidazol -2-il pirimidinas y pirazinas como moduladores del receptor h4 de histamina

Info

Publication number
UY30253A1
UY30253A1 UY30253A UY30253A UY30253A1 UY 30253 A1 UY30253 A1 UY 30253A1 UY 30253 A UY30253 A UY 30253A UY 30253 A UY30253 A UY 30253A UY 30253 A1 UY30253 A1 UY 30253A1
Authority
UY
Uruguay
Prior art keywords
benzoimidazol
pyrimidines
pirazins
modulators
histamine
Prior art date
Application number
UY30253A
Other languages
English (en)
Inventor
Jennifer D Venable
David E Kindrachuk
James P Edwards
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38581554&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY30253(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of UY30253A1 publication Critical patent/UY30253A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)

Abstract

Benzoimidazol-2-il pirimidinas y pirazinas, composiciones farmacéuticas y métodos para el tratamiento de estados de enfermedades, trastornos y afecciones mediadas por la actividad del receptor H4, que incluyen alergia, asma, enfermedades autoinmunes y prurito.
UY30253A 2006-03-31 2007-04-02 Benzoimidazol -2-il pirimidinas y pirazinas como moduladores del receptor h4 de histamina UY30253A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78819006P 2006-03-31 2006-03-31

Publications (1)

Publication Number Publication Date
UY30253A1 true UY30253A1 (es) 2007-08-31

Family

ID=38581554

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30253A UY30253A1 (es) 2006-03-31 2007-04-02 Benzoimidazol -2-il pirimidinas y pirazinas como moduladores del receptor h4 de histamina

Country Status (34)

Country Link
US (6) US7507737B2 (es)
EP (1) EP2007752B1 (es)
JP (1) JP5066175B2 (es)
KR (1) KR101054325B1 (es)
CN (1) CN101460483B (es)
AR (1) AR059380A1 (es)
AT (1) ATE478067T1 (es)
AU (1) AU2007235576B2 (es)
BR (1) BRPI0710083A2 (es)
CA (1) CA2648036C (es)
CO (1) CO6160328A2 (es)
CR (1) CR10413A (es)
CY (1) CY1111169T1 (es)
DE (1) DE602007008545D1 (es)
DK (1) DK2007752T3 (es)
EA (1) EA016264B1 (es)
EC (1) ECSP088815A (es)
ES (1) ES2348829T3 (es)
IL (2) IL194453A0 (es)
ME (1) ME01143B (es)
MX (1) MX2008012655A (es)
NI (1) NI200800260A (es)
NO (1) NO341523B1 (es)
NZ (1) NZ571691A (es)
PE (1) PE20080130A1 (es)
PL (1) PL2007752T3 (es)
PT (1) PT2007752E (es)
RS (1) RS51423B (es)
SI (1) SI2007752T1 (es)
TW (1) TWI400234B (es)
UA (1) UA95949C2 (es)
UY (1) UY30253A1 (es)
WO (1) WO2007117399A2 (es)
ZA (1) ZA200809328B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2348829T3 (es) 2006-03-31 2010-12-15 Janssen Pharmaceutica Nv Benzimidazol-2-il-pirimidinas y pirazinas moduladoras del receptor h4 de histamina.
ES2349237T3 (es) 2006-03-31 2010-12-29 Janssen Pharmaceutica Nv Benzoimidazol-2-il pirimidinas como moduladores del receptor de histamina h4.
US20090069343A1 (en) * 2006-04-10 2009-03-12 Dunford Paul J Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009079001A1 (en) 2007-12-18 2009-06-25 Janssen Pharmaceutica N.V. Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine h4 receptor
CA2727627C (en) * 2008-06-12 2018-02-13 Janssen Pharmaceutica Nv Use of histamine h4 antagonist for the treatment of post-operative adhesions
US8841287B2 (en) 2008-06-12 2014-09-23 Janssen Pharmaceutica N.V. Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor
EP2310012B1 (en) * 2008-06-30 2015-03-04 Janssen Pharmaceutica N.V. Process for the preparation of substituted pyrimidine derivatives
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
TW201018668A (en) 2008-06-30 2010-05-16 Janssen Pharmaceutica Nv Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives
AU2013204436B2 (en) * 2008-06-30 2014-12-04 Janssen Pharmaceutica Nv Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives
AR074209A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina utiles para el tratamiento del cancer
AR074210A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina como inhibidores de ptk2-quinasa
EP2201982A1 (en) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
SG174125A1 (en) * 2009-04-02 2011-10-28 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531510B1 (en) 2010-02-01 2014-07-23 Novartis AG Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
EP2681200A4 (en) 2011-03-03 2015-05-27 Zalicus Pharmaceuticals Ltd INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP3378476A1 (en) 2012-06-08 2018-09-26 Sensorion H4 receptor inhibitors for treating tinnitus
BR112015021463A8 (pt) 2013-03-06 2019-11-19 Janssen Pharmaceutica Nv moduladores de benzoimidazol-2-il pirimidina do receptor histamínico h4,seu uso e composição faramacêutica
GB201504689D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
US9796699B2 (en) * 2015-11-03 2017-10-24 Janssen Pharmaceutica Nv Substituted 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3005852A (en) 1959-12-22 1961-10-24 Gen Aniline & Film Corp Production of sulfoxides and sulfones
GB1062357A (en) 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
US3931195A (en) 1971-03-03 1976-01-06 Mead Johnson & Company Substituted piperidines
US4191828A (en) 1976-04-14 1980-03-04 Richardson-Merrell Inc. Process for preparing 2-(2,2-dicyclohexylethyl)piperidine
US4337341A (en) 1976-11-02 1982-06-29 Eli Lilly And Company 4a-Aryl-octahydro-1H-2-pyrindines
US4190601A (en) 1978-05-31 1980-02-26 Union Carbide Corporation Production of tertiary amines by reductive alkylation
JPS5942396A (ja) 1982-09-02 1984-03-08 Ishihara Sangyo Kaisha Ltd リン酸アミド誘導体およびそれらを含有する殺虫、殺ダニ、殺線虫剤
JPS6130576A (ja) 1984-07-24 1986-02-12 Ube Ind Ltd ２−アミノ−５−シアノピリミジンの製法
AU674553B2 (en) 1992-10-14 1997-01-02 Merck & Co., Inc. Fibrinogen receptor antagonists
GB9410031D0 (en) * 1994-05-19 1994-07-06 Merck Sharp & Dohme Therapeutic agents
GB9422391D0 (en) 1994-11-05 1995-01-04 Solvay Interox Ltd Oxidation of organosulphur compounds
BR9509985A (pt) 1995-12-12 1998-11-03 Omeros Med Sys Inc Solução para irrigação e método para inibição de dor inflamação e esparmo
US5880140A (en) 1996-04-03 1999-03-09 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
US5883105A (en) * 1996-04-03 1999-03-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2000507591A (ja) 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
JP2000507595A (ja) 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシルプロテイントランスフェラーゼの阻害剤
US5939439A (en) * 1996-12-30 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2001509176A (ja) 1997-01-17 2001-07-10 メルク エンド カンパニー インコーポレーテッド インテグリンアンタゴニスト
US5945422A (en) 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
EP0973396A4 (en) 1997-04-07 2001-02-07 Merck & Co Inc METHOD FOR TREATING CANCER
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
US6399612B1 (en) 1997-10-06 2002-06-04 Warner-Lambert Company Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
KR20010041015A (ko) 1998-02-17 2001-05-15 윌리엄 제이. 리플린 항바이러스성 피리미딘 유도체
WO1999065897A1 (en) 1998-06-19 1999-12-23 Chiron Corporation Inhibitors of glycogen synthase kinase 3
ES2195510T3 (es) 1999-03-25 2003-12-01 Synthon Bv Derivados de imidazopiridina y procedimiento para prepararlos.
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
PL206826B1 (pl) 1999-06-23 2010-09-30 Sanofi Aventis Deutschland Podstawione benzimidazole
TWI279402B (en) 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
PL354675A1 (en) 1999-09-30 2004-02-09 Neurogen Corporation Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
ID30204A (id) 1999-12-27 2001-11-15 Japan Tobacco Inc Senyawa-senyawa cincin terfusi dan penggunaannya sebagai obat
DE10006453A1 (de) 2000-02-14 2001-08-16 Bayer Ag Piperidylcarbonsäuren als Integrinantagonisten
PT1473036E (pt) 2000-04-24 2006-10-31 Teva Pharma Solvato de hemitartarato de zolpidem
US6599926B2 (en) 2000-06-23 2003-07-29 Bristol-Myers Squibb Company Heteroaryl-phenyl substituted factor Xa inhibitors
RU2276142C2 (ru) 2000-07-21 2006-05-10 Зингента Партисипейшнс Аг Способ получения 4,6-диметокси-2-метилсульфонилпиримидина (варианты) и применение
KR100860827B1 (ko) 2000-09-06 2008-09-30 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 글리코겐 합성효소 키나아제 3의 억제제
JP2004517074A (ja) * 2000-11-20 2004-06-10 ファルマシア・コーポレーション 凝血カスケードを選択的に阻害するのに有用な置換された多環アリールおよびヘテロアリールピリジン類
US20030130264A1 (en) 2001-02-16 2003-07-10 Tularik Inc. Methods of using pyrimidine-based antiviral agents
JP4544820B2 (ja) 2001-03-09 2010-09-15 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 複素環化合物
EP1370250A2 (en) 2001-03-23 2003-12-17 Chugai Seiyaku Kabushiki Kaisha Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
US20050107400A1 (en) 2001-03-30 2005-05-19 Boyd Leslie F. Use of pyrazolopyridines as therapeutic compounds
WO2002089738A2 (en) * 2001-05-08 2002-11-14 Yale University Proteomimetic compounds and methods
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
BR0213683A (pt) 2001-11-05 2004-10-26 Merck Patent Gmbh Hidrazono-malonitrilas
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
EP1472248A1 (en) * 2002-01-17 2004-11-03 Eli Lilly And Company Modulators of acetylcholine receptors
TWI270542B (en) 2002-02-07 2007-01-11 Sumitomo Chemical Co Method for preparing sulfone or sulfoxide compound
US7314937B2 (en) * 2002-03-21 2008-01-01 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses
EP1539151B1 (en) 2002-08-02 2009-03-18 Genesoft Pharmaceuticals, Inc. Biaryl compounds having anti-infective activity
BR0314059A (pt) 2002-09-06 2005-07-05 Janssen Pharmaceutica Nv Compostos heterocìclicos
PT1543011E (pt) 2002-09-06 2006-08-31 Janssen Pharmaceutica Nv Composto de tienopirrolilo e furanopirrolilo e sua utilizacao como ligandos do receptor h4 da histamina
CN1694703A (zh) * 2002-09-06 2005-11-09 詹森药业有限公司 吲哚基衍生物在制备治疗变应性鼻炎的药物中的用途
US20040127395A1 (en) 2002-09-06 2004-07-01 Desai Pragnya J. Use of histamine H4 receptor modulators for the treatment of allergy and asthma
WO2004029204A2 (en) * 2002-09-27 2004-04-08 Merck & Co., Inc. Substituted pyrimidines
TW200501960A (en) 2002-10-02 2005-01-16 Bristol Myers Squibb Co Synergistic kits and compositions for treating cancer
US20040105856A1 (en) 2002-12-02 2004-06-03 Robin Thurmond Use of histamine H4 receptor antagonist for the treatment of inflammatory responses
JP2006509014A (ja) 2002-12-04 2006-03-16 ジーン ロジック インコーポレイテッド メラノコルチンレセプターの調節因子
WO2004099209A1 (en) 2003-05-05 2004-11-18 F. Hoffmann-La-Roche Ag Fused pyrimidine derivatives with crf activity
EP1628666B1 (en) 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Compouds and uses thereof in modulating amyloid beta
SE0302116D0 (sv) 2003-07-21 2003-07-21 Astrazeneca Ab Novel compounds
CA2528805A1 (en) 2003-08-13 2005-05-06 Chiron Corporation Gsk-3 inhibitors and uses thereof
JP5042626B2 (ja) * 2003-09-22 2012-10-03 エス＊バイオ プライベート リミティッド ベンズイミダゾール誘導体：製造及び医薬適用
MXPA06003578A (es) 2003-09-30 2006-08-31 Johnson & Johnson Compuestos de quinoxalina.
TW200526637A (en) * 2003-09-30 2005-08-16 Janssen Pharmaceutica Nv Benzoimidazole compounds
EP1670739A4 (en) 2003-10-08 2007-08-08 Bristol Myers Squibb Co CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS
US20070099938A1 (en) 2003-10-24 2007-05-03 Ono Pharmaceutical Co., Ltd. Antistress drug and medical use thereof
US8277831B2 (en) 2004-02-17 2012-10-02 Advanced Technologies And Regenerative Medicine, Llc. Drug-enhanced adhesion prevention
EA011242B1 (ru) 2004-03-25 2009-02-27 Янссен Фармацевтика Н.В. Производные имидазола
EP1757594A4 (en) 2004-05-31 2007-12-12 Banyu Pharma Co Ltd quinazoline derivative
CA2572218C (en) * 2004-06-30 2013-06-11 Janssen Pharmaceutica, N.V. Aryl-substituted benzimidazole and imidazopyridine ethers as anti-cancer agents
WO2006025567A1 (ja) 2004-08-31 2006-03-09 Banyu Pharmaceutical Co., Ltd. 新規置換イミダゾール誘導体
WO2006042102A2 (en) * 2004-10-05 2006-04-20 Neurogen Corporation Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
US7381732B2 (en) * 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
US7442716B2 (en) 2004-12-17 2008-10-28 Merck Frosst Canada Ltd. 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
WO2006063466A1 (en) 2004-12-17 2006-06-22 Merck Frosst Canada Ltd. 2-(phenyl or heterocyclic)-1h-phenantrho[9,10-d]imidazoles as mpges-1 inhibitors
CA2602583A1 (en) 2005-03-24 2006-09-28 Janssen Pharmaceutica N.V. Biaryl derived amide modulators of vanilloid vr1 receptor
WO2007044085A2 (en) 2005-05-19 2007-04-19 Xenon Pharmaceuticals Inc. Heteroaryl compounds and their uses as therapeutic agents
US8193206B2 (en) * 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
AU2006259525B2 (en) 2005-06-14 2012-05-24 Gpcr Therapeutics, Inc Pyrimidine compounds
KR101286569B1 (ko) 2005-07-04 2013-07-23 하이 포인트 파마슈티칼스, 엘엘씨 신규 약제
KR101326438B1 (ko) 2005-07-06 2013-11-07 지이 헬스케어 바이오-사이언시스 에이비 분리 매트릭스의 제조 방법
JP2009507896A (ja) 2005-09-13 2009-02-26 パラウ・フアルマ・ソシエダツド・アノニマ ヒスタミンｈ４受容体活性の調節剤としての２−アミノピリミジン誘導体
AU2006325294B2 (en) 2005-10-31 2012-10-11 Merck Sharp & Dohme Corp. CETP inhibitors
TW200800201A (en) 2005-11-18 2008-01-01 Lilly Co Eli Pyrimidinyl benzothiophene compounds
EP1956009A1 (en) * 2005-12-02 2008-08-13 Mitsubishi Tanabe Pharma Corporation Aromatic compound
EP1989187A4 (en) 2006-02-24 2009-07-08 Merck Frosst Canada Ltd 2- (PHENYL OR HETEROCYCLYL) -1H-PHENANTHRO (9,10-D) IMIDAZOLE
CN101032483B (zh) 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
ES2348829T3 (es) * 2006-03-31 2010-12-15 Janssen Pharmaceutica Nv Benzimidazol-2-il-pirimidinas y pirazinas moduladoras del receptor h4 de histamina.
ES2349237T3 (es) 2006-03-31 2010-12-29 Janssen Pharmaceutica Nv Benzoimidazol-2-il pirimidinas como moduladores del receptor de histamina h4.
EP2010172B1 (en) 2006-04-07 2012-08-29 Janssen Pharmaceutica N.V. Indoles and benzoimidazoles as modulators of the histamine h4 receptor
US20090069343A1 (en) 2006-04-10 2009-03-12 Dunford Paul J Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus
EP2019675A4 (en) 2006-05-02 2011-03-02 Merck Frosst Canada Ltd METHODS FOR TREATING OR PREVENTING NEOPLASIA
WO2007134434A1 (en) 2006-05-18 2007-11-29 Merck Frosst Canada Ltd. Phenanthrene derivatives as mpges-1 inhibitors
AU2007272956B2 (en) 2006-07-11 2013-05-02 Janssen Pharmaceutica, N.V. Benzofuro-and benzothienopyryimidine modulators of the histamine H4 receptor
US8779154B2 (en) 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
CL2008000467A1 (es) 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma
WO2009068512A1 (en) 2007-11-30 2009-06-04 Palau Pharma, S. A. 2 -amino-pyrimidine derivatives as histamine h4 antagonists
WO2009079001A1 (en) 2007-12-18 2009-06-25 Janssen Pharmaceutica N.V. Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine h4 receptor
US20090181242A1 (en) 2008-01-11 2009-07-16 Enniss James P Exterior window film
CA2727627C (en) 2008-06-12 2018-02-13 Janssen Pharmaceutica Nv Use of histamine h4 antagonist for the treatment of post-operative adhesions
US8841287B2 (en) 2008-06-12 2014-09-23 Janssen Pharmaceutica N.V. Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor
EP2310012B1 (en) 2008-06-30 2015-03-04 Janssen Pharmaceutica N.V. Process for the preparation of substituted pyrimidine derivatives
TW201018668A (en) 2008-06-30 2010-05-16 Janssen Pharmaceutica Nv Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives
US8852569B2 (en) 2008-08-28 2014-10-07 The General Hospital Corporation Prevention and treatment of itch with cysteine protease inhibition
TWI519533B (zh) 2010-11-01 2016-02-01 Ｌｇ生命科學有限公司 １－｛（２Ｓ）－２－胺基－４－［２，４－雙（三氟甲基）－５，８－二氫吡啶并［３，４－ｄ］嘧啶－７（６Ｈ）－基］－４－側氧丁基｝－５，５－二氟哌啶－２－酮酒石酸鹽之水合物
EP2465498A1 (en) 2010-11-23 2012-06-20 Faes Farma, S.A. Diphenyl-amine derivatives: uses, process of synthesis and pharmaceutical compositions
BR112015021463A8 (pt) 2013-03-06 2019-11-19 Janssen Pharmaceutica Nv moduladores de benzoimidazol-2-il pirimidina do receptor histamínico h4,seu uso e composição faramacêutica

Also Published As

Publication number Publication date
EP2007752A2 (en) 2008-12-31
ZA200809328B (en) 2009-12-30
US8343989B2 (en) 2013-01-01
NO341523B1 (no) 2017-11-27
US20130072510A1 (en) 2013-03-21
IL194453A0 (en) 2009-08-03
US20070244126A1 (en) 2007-10-18
ME01143B (me) 2013-03-20
US20140038995A1 (en) 2014-02-06
IL244946A (en) 2017-03-30
JP5066175B2 (ja) 2012-11-07
EA016264B1 (ru) 2012-03-30
BRPI0710083A2 (pt) 2011-08-02
ECSP088815A (es) 2008-11-27
EP2007752B1 (en) 2010-08-18
IL244946A0 (en) 2016-05-31
PT2007752E (pt) 2010-10-18
RS51423B (en) 2011-02-28
CA2648036C (en) 2012-05-22
AR059380A1 (es) 2008-04-09
US8962644B2 (en) 2015-02-24
ES2348829T3 (es) 2010-12-15
UA95949C2 (ru) 2011-09-26
CA2648036A1 (en) 2007-10-18
CR10413A (es) 2009-02-19
DK2007752T3 (da) 2010-11-15
PE20080130A1 (es) 2008-02-25
PL2007752T3 (pl) 2011-02-28
US7507737B2 (en) 2009-03-24
US20090137608A1 (en) 2009-05-28
ATE478067T1 (de) 2010-09-15
KR20080108586A (ko) 2008-12-15
CO6160328A2 (es) 2010-05-20
CN101460483A (zh) 2009-06-17
TWI400234B (zh) 2013-07-01
CN101460483B (zh) 2013-05-08
NO20084540L (no) 2008-10-28
SI2007752T1 (sl) 2010-12-31
EP2007752A4 (en) 2009-04-22
NI200800260A (es) 2012-01-24
DE602007008545D1 (de) 2010-09-30
US20150148361A1 (en) 2015-05-28
AU2007235576A1 (en) 2007-10-18
EA200870400A1 (ru) 2009-04-28
TW200808737A (en) 2008-02-16
WO2007117399A2 (en) 2007-10-18
KR101054325B1 (ko) 2011-08-04
WO2007117399A3 (en) 2008-09-12
AU2007235576B2 (en) 2011-11-10
CY1111169T1 (el) 2015-06-11
US8598189B2 (en) 2013-12-03
US9365548B2 (en) 2016-06-14
NZ571691A (en) 2011-07-29
JP2009532366A (ja) 2009-09-10
MX2008012655A (es) 2008-12-16
US20100256373A1 (en) 2010-10-07

Similar Documents

Publication Publication Date Title
UY30253A1 (es) Benzoimidazol -2-il pirimidinas y pirazinas como moduladores del receptor h4 de histamina
ECSP099582A (es) Moduladores 2-aminopirimidina del receptor de histamina h4
CO6321192A2 (es) Moduladores de diamino-piridina pirimidina y piridazina del receptor h4 de histamina
DOP2016000027A (es) Moduladores benzoimidazol-2-ilpirimidinas del receptor h4 de histamina
UY30479A1 (es) Moduladores de benzofuro- y benzotienopirimidina del receptor de histamina h4
HK1124767A1 (en) Benzoimidazol-2-yl pyridines as modulators of the histamine h4 receptor
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
JO2694B1 (en) Pyramidines Benzo Imidazole-2-IL and Pyrazinate as histamine H4 receptor regulators
AR095033A1 (es) Moduladores benzoimidazol-2-il pirimidina modulares del receptor de histamina h₄
UA106046C2 (uk) Діамінопіридинові, піримідинові і піридазинові модулятори гістамінового рецептора h4
BR112012010131A2 (pt) arilindenopirimidinas aril-substituídas e seu uso como antagonistas altamente seletivos do receptor de adenosina a2a
CL2010001414A1 (es) Compuestos derivados de diaminopiridina, pirimidina o piridazina, moduladores del receptor h4; composicion farmaceutica que lo comprende; y uso en el tratamiento de trastornos alergicos, dermatologicos, linfaticos, inmunodeficiencias, o enfermedades autoinmunes, entre otras.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20180807